Table 3.
Univariable and Multivariable Multilevel Logistic Regression Model Evaluating the Odds of Adequate Cardiac Monitoring Among a Cohort of Patients Older Than Age 66 Years With Breast Cancer Treated With Adjuvant Trastuzumab
| Variable | Univariable |
Multivariable* |
||
|---|---|---|---|---|
| Crude OR (95% CI) | P | Adjusted OR (95% CI) | P | |
| Patients variables | ||||
| Age, years | ||||
| 66-70 | Reference | Reference | ||
| 71-75 | 0.83 (0.68 to 1.01) | .06 | 0.96 (0.78 to 1.18) | .68 |
| 76-80 | 0.61 (0.48 to 0.79) | < .001 | 0.78 (0.60 to 1.01) | .06 |
| > 80 | 0.75 (0.56 to 1.01) | .05 | 0.87 (0.62 to 1.23) | .43 |
| Year of diagnosis | ||||
| 2005 | Reference | Reference | ||
| 2006 | 1.14 (0.87 to 1.50) | .34 | 1.19 (0.91 to 1.56) | .2 |
| 2007 | 1.35 (1.01 to 1.79) | .04 | 1.42 (1.07 to 1.88) | .01 |
| 2008 | 1.52 (1.13 to 2.05) | .006 | 1.65 (1.21 to 2.27) | .001 |
| 2009 | 1.54 (1.14 to 2.06) | .004 | 1.83 (1.32 to 2.54) | < .001 |
| Race/ethnicity | ||||
| White | Reference | Reference | ||
| Hispanic | 0.76 (0.55 to 1.05) | .09 | 0.79 (0.56 to 1.12) | .18 |
| Black | 0.94 (0.65 to 1.35) | .73 | 0.82 (0.56 to 1.20) | .31 |
| Other | 0.84 (0.54 to 1.31) | .45 | 0.87 (0.56 to 1.35) | .54 |
| Marital status | ||||
| Married | Reference | Reference | ||
| Not married | 0.87 (0.70 to 1.14) | .12 | 0.93 (0.77 to 1.13) | .48 |
| Unknown | 0.54 (0.30 to 0.97) | .04 | 0.61 (0.36 to 1.03) | .06 |
| Education | ||||
| 1st quartile (highest) | Reference | Reference | ||
| 2nd quartile | 0.90 (0.72 to 1.17) | .37 | 0.80 (0.62 to 1.05) | .1 |
| 3rd quartile | 0.96 (0.72 to 1.18) | .73 | 0.90 (0.67 to 1.22) | .51 |
| 4th quartile (lowest) | 0.76 (0.59 to 0.98) | .03 | 0.92 (0.62 to 1.34) | .65 |
| Poverty | ||||
| 1st quartile (lowest) | Reference | Reference | ||
| 2nd quartile | 1.04 (0.81 to 1.33) | .75 | 1.14 (0.88 to 1.48) | .33 |
| 3rd quartile | 0.99 (0.77 to 1.27) | .93 | 1.07 (0.77 to 1.48) | .69 |
| 4th quartile (highest) | 0.78 (0.78 to 0.98) | .06 | 0.96 (0.64 to 1.43) | .83 |
| Urban/rural | ||||
| Big metropolitan | Reference | Reference | ||
| Metropolitan | 0.91 (0.73 to 1.12) | .37 | 0.96 (0.75 to 1.23) | .76 |
| Urban | 1.00 (0.69 to 1.44) | .99 | 1.22 (0.81 to 1.85) | .34 |
| Less urban | 0.93 (0.68 to 1.28) | .68 | 1.01 (0.70 to 1.47) | .94 |
| Rural | 0.91 (0.44 to 1.90) | .79 | 1.06 (0.53 to 2.11) | .86 |
| Comorbidity | ||||
| 0 | Reference | Reference | ||
| 1 | 1.00 (0.81 to 1.24) | .99 | 1.18 (0.94 to 1.48) | .15 |
| 2+ | 0.84 (0.60 to 1.18) | .32 | 1.13 (0.80 to 1.60) | .49 |
| Stage | ||||
| Localized | Reference | Reference | ||
| Regional | 0.91 (0.76 to 1.07) | .25 | 0.84 (0.70 to 1.02) | .074 |
| Anthracycline | ||||
| No | Reference | Reference | ||
| Yes | 1.28 (1.08 to 1.53) | .005 | 1.39 (1.14 to 1.71) | .001 |
| Taxane | ||||
| No | Reference | Reference | ||
| Yes | 1.24 (1.00 to 1.55) | .05 | 1.02 (0.81 to 1.28) | .89 |
| Hypertension | ||||
| No | Reference | Reference | ||
| Yes | 0.96 (0.81 to 1.14) | .64 | 0.99 (0.81 to 1.20) | .89 |
| CAD | ||||
| No | Reference | Reference | ||
| Yes | 0.75 (0.53 to 1.06) | .10 | 0.86 (0.61 to 1.22) | .40 |
| Physician variables | ||||
| Decade of graduation | ||||
| Prior to 1980 | Reference | Reference | ||
| 1980-1989 | 1.2 (0.94 to 1.52) | .45 | 1.21 (0.95 to 1.55) | .12 |
| After 1990 | 1.93 (1.53 to 2.44) | < .001 | 1.66 (1.29 to 2.12) | < .001 |
| Training location | ||||
| United States | Reference | Reference | ||
| Not United States | 1.01 (0.82 to 1.25) | .91 | 1.09 (0.88 to 1.36) | .43 |
| Degree | ||||
| MD | Reference | Reference | ||
| DO | 1.31 (0.73 to 2.35) | .37 | 1.06 (0.53 to 2.12) | .86 |
| Board certified | ||||
| Yes | Reference | Reference | ||
| No | 1.17 (0.74 to 1.86) | .50 | 1.12 (0.65 to 1.94) | .68 |
| Sex of physician | ||||
| Male | Reference | Reference | ||
| Female | 1.75 (1.42 to 2.16) | < .001 | 1.37 (1.10 to 1.70) | .005 |
Abbreviations: CAD, coronary artery disease; OR, odds ratio.
*
Variables in the model also included SEER and Texas Cancer Registry region, type of surgery, radiation therapy, estrogen receptor, and progesterone receptor.